Have you or a loved one been diagnosed with cancer, heart failure or bullous pemphigoid after taking Kombiglyze XR? Are you interested in filing a class action lawsuit against the manufacturers? If so, we can help.
Free Confidential Lawsuit Evaluation: If you or a loved one got pancreatic cancer after taking Kombiglyze XR, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
Table Of Contents
- Update: MDL Proposed for Kombiglyze XR Heart Failure Lawsuits
- Kombiglyze and Pancreatic Cancer
- Pancreatic Cancer Symptoms
- Saxagliptin (Onglyza, Kombiglyze) Linked to Heart Failure: FDA Warning
- Bullous Pemphigoid
- Thyroid Cancer
- Bristol-Myers Squibb, AstraZeneca Sued for Kombiglyze Heart Failure
- Why Our Law Firm Is Filing Individual Lawsuits Opposed To a Class Action
- Get a Free Kombiglyze XR Lawsuit Evaluation With Our Lawyers
Update: MDL Proposed for Kombiglyze XR Heart Failure Lawsuits
Nov. 1, 2017 – A man alleging to have developed heart failure from the use of Onglyza has requested multidistrict litigation (MDL) status for his and all other similar claims. Plaintiff suggested the Northern District of California as the venue for the proposed litigation, noting that several cases have already been filed there, and that at least one plaintiff is based in San Francisco.
Kombiglyze and Pancreatic Cancer
Recent studies indicate that incretin mimetic diabetes medications like Kombiglyze XR, which affect the GLP-1 metabolic pathway, can potentially increase the risk of pancreatitis and pancreatic cancer. Beginning in 2007, the FDA began issuing healthcare provider alerts  about reports of acute pancreatitis (including hemorrhagic and necrotizing pancreatitis) in patients who used the incretin mimetic Byetta pen.
Pancreatic Cancer Symptoms
- Itchy skin / rashes
- Mouth ulcers
- White coated tongue
- Toe fungus
Saxagliptin (Onglyza, Kombiglyze) Linked to Heart Failure: FDA Warning
FDA has requested clinical trial data  from manufacturers of saxagliptin-containing diabetes medications (Onglyza & Kombiglyze XR) regarding their potential to cause heart failure. The agency’s request was the result of a study published in the New England Journal of Medicine (NEJM)  that found an increased rate of heart failure among diabetics treated with saxagliptin. FDA’s analysis of saxagliptin clinical trials is part of a broader evaluation of the cardiovascular risks posed by type 2 diabetes drug therapies.
Kombiglyze XR and other type 2 diabetes medications from the DPP-4 inhibitor class may cause bullous pemphigoid (BP), a rare but extremely painful skin reaction with blisters and lesions, the FDA warned in December 2016. BP occurs when the immune system accidentally produces antibodies that attack the fibers that connect the outer layer of skin (epidermis) to the lower layers (dermis). When the antibodies attack, the skin separates and causes a red rash, skin eruptions, and blisters. Several diabetes patients treated with DPP-4 inhibitors developed bullous pemphigoid, 50% of them were hospitalized and one person died. The manufacturers of all DPP-4 diabetes drugs updated warning labels in January 2017.
In 2011, a study published in the medical journal Gastroenterology (PDF)  identified 32 reports of thyroid cancer associated with Januvia (sitagliptin) or Byetta (exenatide), incretin mimetics in the same class as Kombiglyze XR.
Other studies of laboratory rats who were given the incretin mimetic Victoza (liraglutide) indicated that the drug caused malignant thyroid tumors. Although it is unknown whether Victoza or Kombiglyze actually cause cancer, the study was alarming enough that the FDA published a Safety Communication  to warn about the risk of thyroid cancer.
Bristol-Myers Squibb, AstraZeneca Sued for Kombiglyze Heart Failure
July 24, 2017 – A New Jersey man who claims that he developed coronary artery disease and congestive heart failure after taking saxagliptin has filed a products liability lawsuit against Bristol-Myers Squibb and AstraZeneca Pharmaceuticals. Plaintiff Earl Binns alleges that the drugmakers are responsible for his injuries because they had known for years that the diabetes drug could increase the risk of catastrophic heart damage.
Why Our Law Firm Is Filing Individual Lawsuits Opposed To a Class Action
In some instances, a class action may offer some advantages, as they aggregate a large number of individualized claims into one representational lawsuit. The aggregation can increase the efficiency of the legal process, lower the costs of litigation and in some cases offer the solution to a common problem wherein small recoveries do not provide the incentive for any individual or law firm to file an individual lawsuit.
However, a class action suit can also be a detriment to many class members, as they are often forced into a blanket “low ball settlement” and higher attorney fees. At Schmidt & Clark, LLP we understand that our clients are suffering emotionally and economically due to loss of wages and/or high medical bills and we plan to maximize each clients recovery by filing individual Kombiglyze XR lawsuits on their behalf.
See all dangerous drugs cases which we’re currently handling.
Get a Free Kombiglyze XR Lawsuit Evaluation With Our Lawyers
The Pharmaceutical Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Kombiglyze lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Case Evaluation: Again, if you developed cancer or heart failure from Kombiglyze XR, you should contact S&C law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.